Literature DB >> 17215687

Epidemiology of vertigo.

Hannelore K Neuhauser1.   

Abstract

PURPOSE OF REVIEW: Epidemiological findings on the distribution, determinants and outcome of vertigo can be used for clinical decision making and can help understand the underlying causes of vestibular diseases. This article gives an overview of the epidemiology of the vestibular symptom vertigo and of four specific vestibular disorders: benign paroxysmal positional vertigo, migrainous vertigo, Menière's disease and vestibular neuritis. RECENT
FINDINGS: Based on a neurotologic survey of the general population, 1-year prevalence estimates for vertigo were 4.9%, for migrainous vertigo 0.89% and for benign paroxysmal positional vertigo 1.6%. Diagnostic positional manoeuvres and treatments for benign paroxysmal positional vertigo, however, are still not being done by most doctors. The female preponderance among patients with benign paroxysmal positional vertigo and migrainous vertigo may be linked to migraine but is not fully understood. A recently reported prevalence of Menière's disease of 0.51% is much higher than previous estimates. Follow-up studies have shown benign paroxysmal positional vertigo recurrence rates of 50% at 5 years and a persistence of dizziness related to anxiety in almost a third of patients 1 year after vestibular neuritis.
SUMMARY: The epidemiology of vertigo and vestibular disorders is still an underdeveloped field. Recent studies have underscored the impact of vertigo at the population level, but its determinants and outcome are not well known yet.

Entities:  

Mesh:

Year:  2007        PMID: 17215687     DOI: 10.1097/WCO.0b013e328013f432

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  84 in total

1.  Cranial Nerve VIII: Hearing and Vestibular Functions.

Authors:  Richard D Sanders; Paulette Marie Gillig
Journal:  Psychiatry (Edgmont)       Date:  2010-03

2.  Causes and time-course of vertigo in an ear, nose, and throat clinic.

Authors:  Suwicha Isaradisaikul; Niramon Navacharoen; Charuk Hanprasertpong; Jaran Kangsanarak; Rapeepun Panyathong
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-06-22       Impact factor: 2.503

3.  Current treatment of vestibular, ocular motor disorders and nystagmus.

Authors:  Michael Strupp; Thomas Brandt
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

4.  Utility of an Abbreviated Dizziness Questionnaire to Differentiate Between Causes of Vertigo and Guide Appropriate Referral: A Multicenter Prospective Blinded Study.

Authors:  Lauren T Roland; Dorina Kallogjeri; Belinda C Sinks; Steven D Rauch; Neil T Shepard; Judith A White; Joel A Goebel
Journal:  Otol Neurotol       Date:  2015-12       Impact factor: 2.311

Review 5.  The treatment and natural course of peripheral and central vertigo.

Authors:  Michael Strupp; Marianne Dieterich; Thomas Brandt
Journal:  Dtsch Arztebl Int       Date:  2013-07-22       Impact factor: 5.594

Review 6.  Vestibular dysfunction: prevalence, impact and need for targeted treatment.

Authors:  Yuri Agrawal; Bryan K Ward; Lloyd B Minor
Journal:  J Vestib Res       Date:  2013       Impact factor: 2.435

Review 7.  Migraine-associated vertigo: diagnosis and treatment.

Authors:  Yoon-Hee Cha
Journal:  Semin Neurol       Date:  2010-03-29       Impact factor: 3.420

8.  Prevalence of Persistent Tinnitus and Dizziness in an Elderly Population in Southern Taiwan.

Authors:  Ning Chia Chang; Chia Yen Dai; Wen Yi Lin; Hua Ling Yang; Hsun Mo Wang; Chen Yu Chien; Kuen Yao Ho
Journal:  J Int Adv Otol       Date:  2019-04       Impact factor: 1.017

9.  STANDING, a four-step bedside algorithm for differential diagnosis of acute vertigo in the Emergency Department.

Authors:  S Vanni; R Pecci; C Casati; F Moroni; M Risso; M Ottaviani; P Nazerian; S Grifoni; P Vannucchi
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-12       Impact factor: 2.124

Review 10.  Migraine-associated risks and comorbidity.

Authors:  H C Diener; M Küper; T Kurth
Journal:  J Neurol       Date:  2008-09-30       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.